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DObjectives: To identify novel predictors for coronary artery bypass grafting failure, we probed for associations
with known clinical and biochemical risk factors for atherosclerosis. We also used microarray analysis to
identify novel single nucleotide polymorphisms to better understand the genetics and pathogenesis of graft
occlusion.
Methods: The present study was a nested case-control substudy of the Radial Artery Patency Study 5-year
follow-up data. From 1996 to 2001, 87 patients underwent coronary artery bypass grafting. Of these, 26 patients
(29.9%) had an occluded study graft (saphenous vein or radial artery) at 8.0 1.1 years. The clinical parameters,
late angiography, blood biomarker levels, and surgical outcomes data were included in a multivariate analysis to
determine the independent predictors of graft failure.
Results: The risk factors of graft failure were fibrinogen (odds ratio [OR], 3.94; 95% confidence interval [CI],
1.33-11.63; P¼ .01), creatinine (OR, 1.06; 95%CI, 1.02-1.10; P¼ .006), and diabetes mellitus (OR, 5.15; 95%
CI, 1.08-24.59; P ¼ .04). High-density lipoprotein (OR, 0.74; 95% CI, 0.53-1.02; P ¼ .06) was weakly
protective; however, low-density lipoprotein and total cholesterol were not predictors. We then identified the
association of several human single nucleotide polymorphisms with graft failure, including mutations in
glutathione-S-transferase a3. Human coronary arteries and bypass grafts demonstrated increased protein
expression of glutathione-S-transferase a3, a known cardioprotective factor, in the atherosclerotic regions
and surrounding adventitial tissues.
Conclusions: We identified diabetes as a potential clinical predictor and plasma fibrinogen, creatinine, and
high-density lipoprotein as potential novel biomarkers. These might help risk stratify patients for the
development of graft failure. We also demonstrated a novel association between glutathione-S-transferase a3
and graft failure. (J Thorac Cardiovasc Surg 2014;148:515-20)Supplemental material is available online.e Divisions of Cardiac Surgerya and Cardiology,g Schulich Heart Centre, Sun-
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The Journal of Thoracic and CaCoronary artery bypass grafting (CABG) is an effective
treatment of complex, multivessel coronary artery disease.1
Graft failure is a surrogate marker for future cardiac events,
including repeat revascularization, myocardial infarction,
and death.2,3 The multi-institutional Collaborative Study
in Coronary Artery Surgery found several clinical and
angiographic patient characteristics predictive of graft
occlusion, such as age, female gender, and left ventricular
dysfunction.4 However, the identification of patients at
risk of graft failure continues to be challenging.
The development of a clinically validated panel of
biomarkers to predict graft occlusion would have the
potential to facilitate perioperative measures to prevent
myocardial injury and add valuable prognostic information
by predicting the risk of mortality after CABG. In the
present report, we evaluated the known clinical variables
and plasma levels of the biomarkers of atherosclerosis using
long-term angiograms to identify novel associations that
could potentially be used for the prediction of graft
occlusion after CABG. Furthermore, given that 30% tordiovascular Surgery c Volume 148, Number 2 515
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CTA ¼ computed tomography angiography
GSTa3 ¼ glutathione-S-transferase a3
HDL ¼ high-density lipoprotein
LDL ¼ low-density lipoprotein
OR ¼ odds ratio
SNP ¼ single nucleotide polymorphism
SVG ¼ saphenous vein graft
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D60% of the individual risk of coronary artery disease is
hereditary, it is also likely that graft occlusion is influenced
by genetics.5 Thus, we performed a case-control genome-
wide association study to identify novel single nucleotide
polymorphisms (SNPs) associated with graft failure that
might lead to the identification of genetic predictors of graft
occlusion and novel pathogenetic molecules.METHODS
Study Design
The present study was a nested case-control substudy of the Radial
Artery Patency Study (NCT00187356).6 This multicenter study
involved 561 patients initially enrolled across 13 sites, of whom 269
patients underwent late angiography or computed tomography
angiography (CTA). A total of 87 patients from a single site participated
in the present substudy (of 252 total patients and 150 total patients with
late angiograms or CTA). In brief, each patient had received both a
radial artery graft and a study saphenous vein graft (SVG), and
follow-up examinations were performed at 8.0  1.1 years using
angiography (n ¼ 74) or CTA (n ¼ 13). Peripheral blood samples
were taken at follow-up angiography or CTA for biomarker analysis.
All angiograms and CTAs were reviewed by an independent committee
of 4 experienced cardiologists who were unaware of patient randomiza-
tion (E.A.C., S.R., J.D.D., L.S.). Cases were defined as patients with
1 study grafts that were completely occluded. Controls were defined
as patients with patency of both study grafts. The primary study objec-
tive was to identify the clinical variables, circulating biomarker levels,
and surgical outcomes data associated with bypass graft occlusion.
Our institutional review committee approved the present study, and all
subjects gave written informed consent.
Sample Collection and Biochemical Assay
The peripheral blood samples were centrifuged (15 minutes, 3000 rpm)
and analyzed in triplicate for high-sensitivity C-reactive protein
(Roche Diagnostics, Basel, Switzerland), fibrinogen (Roche Diagnostics),
homocysteine (Roche Diagnostics), interleukin-6 (R&D Systems,
Minneapolis, Minn), interleukin-18 (MBL, Co, Ltd, Nagoya, Japan),
lipoprotein a (Abcam, Cambridge, Mass), total cholesterol (Roche
Diagnostics), high-density lipoprotein (HDL; Roche Diagnostics), low-
density lipoprotein (LDL; Roche Diagnostics), apolipoprotein B (Roche
Diagnostics), and triglycerides (Roche Diagnostics).
DNA Extraction and SNP Characterization
Peripheral blood leukocytes were collected from flash frozen samples.
The DNA was extracted (DNeasy kit, Qiagen, Hilden, Germany) and
multiplex polymerase chain reaction performed. Purified primer extension516 The Journal of Thoracic and Cardiovascular Surgreactions were submitted for hybridization to the Illumina 660W-Quad
Infinium DNA Analysis BeadChips (San Diego, Calif). The criteria for
SNPs were a call rate>95%, SNPs in Hardy-Weinberg equilibrium in con-
trol (P<.0001), a minor allele frequency>1%, and individual samples
with a genotype presence>95%.
Immunohistochemistry
Formalin-fixed and paraffin-embedded human coronary artery and
bypass graft tissues from the autopsy cases were submitted for immunohis-
tochemistry using anti-glutathione-S-transferase a3 (GSTa3; 1:5000;
Abcam, Cambridge, Mass), biotinylated secondary antibody (1:10,000),
and Vector Black Alkaline Phosphatase Substrate Kit (Vector Laboratories,
Burlingame, Calif). All sections were reviewed by a cardiovascular
pathologist (B.M.M.). Quantitative imaging analysis was performed using
ImageProPlus (Media Cybernetics, Rockville, Md). The positive and
negative controls are shown in Figure E1.
Statistical Analysis
Statistical analyses were performed with SPSS (IBM, Somers, NY).
Univariate analyses were performed using the c2 or Fisher exact test for
categorical variables, an independent 2-sample t test for normally distrib-
uted continuous variables, and Wilcoxon rank sum test for continuous
variables, with a nonparametric distribution. The variables with univariate
P<.25 or those of known clinical importance were included in a multivari-
able logistic regression model to calculate the risk-adjusted predictors of
graft occlusion. Model discrimination was evaluated by the area under
the receiver operating characteristic curve, and calibration was assessed
using the Hosmer-Lemeshow goodness-of-fit statistic (P¼ .7).7 The model
was evaluated for collinearity using the variance inflation factor, in which
multicollinearity is considered positive if the variance inflation factor is
>2.5. All variance inflation factors in our model were<2.5. The data are
presented as the median and range or mean  standard deviation.RESULTS
Patient Characteristics, Preoperative Details, and
Operative Outcomes
A total of 87 patients who had undergone CABG from
June 1996 to January 2001 were enrolled in the present
study. The baseline characteristics of the total study
population at enrollment are listed in Table 1. The cases
had greater baseline creatinine levels than the controls
(97.0  21.2 vs 88.1  17.1; P ¼ .05).
The intraoperative variables and postoperative outcomes
are listed in Table 2. A trend was seen for a greater
number of grafts in the case group than in the control group
(3.9  0.7 vs 3.6  0.6; P ¼ .05) associated with a longer
cardiopulmonary bypass time (116.9  25.4 vs 105.3 
26.7 minutes; P¼ .06). No in-hospital mortalities occurred.Late Angiography and CTA
Angiography or CTAwas performed at 8.0 1.1 years of
follow-up for all 87 patients, 7 of which were clinically
directed. Of the 26 patients with an occluded study graft,
5 (5.7%) had an occluded radial artery, 19 (21.8%) an
occluded SVG, and 2 (2.3%) an occluded radial artery
and SVG. Regarding the target vessels, of the occluded
grafts, 16 (57.1%) had been grafted to the circumflex artery
and 12 (42.9%) to the right coronary artery.ery c August 2014












Female gender 28.8 (21) 35.7 (5) .8
Preoperative myocardial infarction 49.2 (30) 42.3 (11) .6
Smoking 75.4 (46) 76.9 (20) .6
Hypertension 59.0 (36) 50.0 (13) .5
Dyslipidemia 75.4 (46) 73.1 (19) .8
Congestive heart failure 3.3 (2) 3.8 (1) 1.0
LVEF
>60% 52.5 (32) 46.2 (12) .6
40%-60% 47.5 (29) 53.8 (14)
Diabetes mellitus 27.9 (17) 42.3 (11) .2
Creatinine (mm/L) 88.1  17.1 97.0  21.2 .05
Preoperative medications
Aspirin 83.6 (51) 84.6 (22) 1.0
b-Blocker 55.7 (34) 73.1 (19) .2
Lipid lowering agent 90.2 (55) 88.5 (23) 1.0
ACEI/ARB 68.9 (40) 57.7 (15) .3
Data presented as n, % (n), or mean  standard deviation. LVEF, Left ventricular
ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker.
TABLE 3. Plasma levels of circulating biomarkers in control and case
groups
Biomarker Control group Case group P value
Apolipoprotein B (g/L) 0.79  0.20 0.69  0.15 .03
C-reactive protein (mg/L) 1.70  1.55 1.91  1.93 .7
Fibrinogen (g/L) 3.19  0.63 2.94  0.77 .2
Total cholesterol (mmol/L) 3.87  0.78 3.73  1.17 .5
HDL (mmol/L) 1.03  0.38 0.95  0.29 .3
Total cholesterol/HDL ratio 4.12  1.40 4.40  2.88 .5
LDL (mmol/L) 2.09  0.73 1.86  0.59 .2
Triglycerides (g/L) 1.68  0.98 1.53  0.71 .9
HbA1c 0.06  0.01 0.07  0.01 .1
Lipoprotein a (mg/dL) 12.0  12.1 12.1  11.4 1.0
Homocysteine (mmol/L) 13.4  4.8 12.6  5.1 .5
NT-BNP (pmol/L) 372.0  456.2 482.9  706.4 .4
Data presented mean  standard deviation. HDL, High-density lipoprotein;
LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; NT-BNP, N-terminal brain
natriuretic peptide.




Blood was submitted for expression of 12 circulating
biomarkers previously associated with atherosclerosis
(Table 3). Paradoxically, apolipoprotein B was significantly
lower in the cases than in the controls (0.69  0.15 vs 0.79
 0.2; P¼ .03). No other significant differences were found
in the biomarker levels between the case and control
patients on univariate analysis. Regarding the lipid levels,
56.6% (47 of 83 patients) had an LDL<2 mmol/L and
66.7% (42 of 63 patients) had an apolipoprotein
B level < 0.8 g/L, meeting the current target for a











105.3  26.7 116.9  25.4 .06
Crossclamp time (min) 89.3  24.9 96.1  29.2 .3
Conduits (n) 3.6  0.6 3.9  0.7 .05
Postoperative variables
Hospital mortality (%) 0 (0) 0 (0) —
Stroke (%) 0 (0) 3.8 (1) .3
Inotrope use (%) 11.5 (7) 7.7 (2) .7
Ventilation duration (h) 7.0 (5.0-9.1) 7.0 (5.0-11.1) .9
Hospital stay (d) 6.4  4.5 8.7  5.4 .03
Angiography after surgery (y) 8.0  1.5 8.0  1.3 .9
Data presented as mean  standard deviation,% (n), or median (interquartile range
[25th-75th]).
The Journal of Thoracic and Caaccording to the Canadian Lipid Guidelines.8 Regarding
the secondary lipid targets, 51.8% (44 of 85 patients) had
a total cholesterol/HDL ratio< 4.0 and 64.7% (55 of 85
patients) had triglycerides<1.7 mmol/L.Predictors of Graft Occlusion
The clinical parameters, circulating biomarker levels, and
surgical outcomes datawere included in a stepwisemultivar-
iate logistic regression analysis to find novel associations
that might lead to independent predictors of graft failure.
Of the biomarkers, fibrinogen was an independent predictor
of graft failure (odds ratio [OR] 3.94; 95% confidence inter-
val [CI], 1.33-11.63; P ¼ .01; Table 4). HDL (OR, 0.74;
95% CI, 0.53-1.02; P¼ .06) was weakly protective against
graft failure, although this did not reach statistical signifi-
cance. Regarding the preoperative characteristics, high
creatinine (OR, 1.06; 95%CI, 1.02-1.10; P¼ .006) and dia-
betesmellitus (OR, 5.15; 95%CI, 1.08-24.59;P¼ .04)were
predictive of graft failure.SNP Association With Graft Failure
Genotypic analysis was performed for 26 case and 61
control patients. The SNPs with the strongest degree of
association with graft failure are shown in Table E1.
The SNP rs1330927, located on chromosome 9p21.3,TABLE 4. Independent multivariate predictors of graft occlusion
Variable
Regression
coefficient OR 95% CI P value
Fibrinogen 1.37  0.55 3.94 1.33-11.63 .01
Creatinine 0.54  0.02 1.06 1.02-1.10 .006
Diabetes mellitus 1.64  0.80 5.15 1.08-24.59 .04
Preoperative b-blocker 1.42  0.64 3.17 1.06-13.2 .04
HDL 0.31  0.17 0.74 0.53-1.02 .06
Reference values: fibrinogen, 1 g/L; creatinine, 1 mmol/L; HDL, 0.1 mmol/L.
OR, Odds ratio; CI, confidence interval; HDL, high-density lipoprotein.
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FIGURE 1. Glutathione-s-transferase a3 (GSTa3) expression in human
coronary arteries (CAs) and saphenous vein grafts (SVGs). Upper,
GSTa3 expression seen in deep intimal layer (arrows) and adventitia
(arrowheads) of atherosclerotic plaque regions of CA (original
magnification 34) but not in the nonatherosclerotic CAs (Insert; original
magnification 340). Lower, Gsta3 expression is present in the intima of
the SVGs undergoing intimal proliferation (arrowheads; original
magnification 320) but not in the patent vein grafts (Insert; original
magnification 320). GSTA3 expression was more abundant in human
atherosclerotic CAs (n ¼ 10) than in the nonatherosclerotic CAs on
quantitative image analysis (n ¼ 6; P<.05).
Acquired Cardiovascular Disease Yanagawa et al
A
C
Da locus strongly associated with atherosclerosis, was
significantly associated with graft occlusion. Also, 5 SNPs
of the glutathione-s-transferase a3 (GSTa3) gene, which
encodes a key regulator of the protective response to
oxidative stress, were found to be associated with graft
failure.
GSTa3 Expression
Atherosclerotic human coronary arteries (n¼ 10), CABG
grafts (n ¼ 10), and normal coronary arteries from patients
with dilated cardiomyopathy (n ¼ 6) were evaluated for
GSTa3 protein expression. Expression of GSTa3 was
prominent in atherosclerotic human coronary arteries in
the deep intimal and adventitial layers (P<.05; Figure 1).
In the human SVGs, GSTa3 expression was demonstrated
in the adventitial tissues in close special association with
the occluded, but not the patent, grafts (Figure 1).
DISCUSSION
In the present report, we have attempted to identify novel
associations among the clinical parameters, circulating
biomarkers, and SNPs with graft failure after CABG.518 The Journal of Thoracic and Cardiovascular SurgWe have demonstrated that fibrinogen and creatinine are
independent predictors of graft failure and HDL might be
independently protective against graft failure and that
diabetes was also independently predictive.4 Several SNPs
of GSTa3 were associated with graft occlusion, and
expression of GSTa3 was increased in the atherosclerotic
regions of the human coronary arteries and tissues adjacent
to the occluded bypass grafts.
Of the patients included in the present study, 29.9% had
1 occluded study graft at angiography or CTA (2 patients
had 2 occluded grafts). Because 8% of the patients (7 of 87)
had clinical indications of myocardial ischemia prompting
angiography, the incidence of graft failure was likely
greater than in the overall post-CABG population.
Consistent with our published findings, the vein grafts
were much more likely to be occluded than the radial artery
grafts.6,9 Improvements in SVG patency compared with
historical data were likely largely owing to improved
antiplatelet and lipid-lowering therapy.10,11 Intensive
lowering of LDL cholesterol after CABG will reduce
major cardiovascular events by 27% and repeat
coronary revascularization by 30%.11 More than 89% of
patients in our study were treated with a statin-based
lipid-lowering regimen preoperatively, and all patients
were treated postoperatively, which was at least partly
responsible for the high rates of LDL, triglycerides, and
total cholesterol/HDL ratio within the targets determined
from the current guidelines.8
In recent years, appreciation has increased for emerging
biochemical and genetic risk factors as predictors of
atherosclerosis and coronary events beyond the traditional
Framingham risk factors.12,13 The promise of biomarkers
is to facilitate the risk stratification of patients using a
simple blood-based test. In the present report, we studied
12 plasma biomarkers with biologic plausibility that
have been demonstrated to be strongly associated with
cardiovascular disease in clinical epidemiologic studies.
Of these, fibrinogen was independently associated with
graft failure, and HDL was weakly protective.
Fibrinogen is a key regulator of thrombosis, and
fibrinogen was an independent risk factor for cardiovascular
disease. A meta-analysis of 154,211 patients from 31
prospective studies demonstrated that elevated fibrinogen
levels were strongly associated with coronary artery disease
(hazard ratio, 2.42; 95% CI, 2.24-2.60).14 The fibrinogen
levels themselves have been associated with inflammation
and hemostasis.15
Clear epidemiologic evidence has shown that HDL is
inversely related to coronary artery disease. An increase
in HDL by 1 mg/dL was associated with a 2% reduction
in coronary artery disease incidence in men and a 3%
reduction in women.16 To our surprise, LDL and total
cholesterol were not independent predictors of graft failure
in our study.ery c August 2014
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DWe also found that diabetes and high plasma creatinine
were predictive of graft failure. The link among renal
insufficiency, hypertension, and dyslipidemia has been
demonstrated, even with mild renal impairment.17 A post
hoc analysis of the Heart Outcomes Prevention Evaluation
study found that the incidence of cerebrovascular death,
myocardial infarction, or stroke was 22.2% with mild renal
insufficiency compared with 15% with normal renal
function.18 The precise mechanism linking elevated
creatinine and graft failure could involve hypertension
secondary to sodium retention, endothelial dysfunction,
inflammation, and oxidative stress.
The strategies of linkage and candidate gene analyses and
genome-wide association studies have already identified
promising SNP associations with coronary artery disease
and its major clinical sequelae, myocardial infarction.19-21
In the present study, we identified several novel SNPs that
are potentially associated with graft failure, including 1
SNP in the 9p21.3 locus. In a large-scale genome-wide
association study, SNPs in the 9p21.3 region were strongly
linked to coronary artery disease, accounting for 10% to
20% of the population attributable risk.20 We also found
several mutations of GSTa3 to be associated with graft
occlusion. Histologically, overexpression of GSTa3 was
found in human coronary atherosclerosis and tissues
adjacent to occluded vein grafts. A member of the GST
superfamily, GSTa3 is a critical enzyme in detoxification
of oxidative and xenobiotic agents.22 GSTs are upregulated
in human atherosclerotic plaques, and GST-overexpressing
endothelial cells are resistant to oxidative injury.23
Considering that oxidative stress and endothelial injury
are key initiating steps in atherosclerosis, the observed
expression of GSTa3 could be a potential protective
mechanism against graft failure. The identification of a
critical gene or pathway associated with graft occlusion
could lead to a novel therapeutic target, possibly by
ex vivo gene transfer. In the Project of Ex-vivo Vein Graft
Engineering via Transfection (PREVENT) IV trial, an
E2F decoy was delivered to vein grafts intended for
CABG, demonstrating the feasibility of such a therapeutic
approach.24
Study Limitations
Some important caveats exist related to our findings.
We could not comment on whether the graft occlusion
event occurred during the acute, subacute, or chronic
postoperative stage. Furthermore, the biomarkers were
measured at a single point, and, as such, the temporal
expression profile is unknown. Thus, it is possible that
alterations in biomarker expression occurred after graft
occlusion and could not be used in a predictive algorithm.
On univariate analysis, lower apolipoprotein B levels
were associated with graft occlusion, a counterintuitive
result that highlights the need for a panel of biomarkersThe Journal of Thoracic and Caand not any single biomarker in predictive algorithms.
Because the patient numbers were small, our SNP data
are preliminary and should be considered hypothesis
generating.
CONCLUSIONS
In the present report, we have demonstrated that clinical
variables such as diabetes and circulating biomarkers such
as high fibrinogen, high creatinine, and low HDL are
independent risk factors for graft occlusion after CABG.
We performed an unbiased genetic association study
that revealed an association between graft occlusion
and mutations in the cardioprotective gene GSTa3, a
promising target for future investigation. The presence of
clinical features and biochemical or genetic biomarkers
associated with graft failure might identify patients who
warrant closer follow-up, medical treatment, or novel
graft-targeted gene therapy, ultimately offering greater
patient-centered care.
The authors would like to thank Cheryl Crozier and Ye Sun at
the Analytical Genetics Technology Centre, University Health
Network, for their genomic support.
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FIGURE E1. Positive and negative immunohistochemical controls for
glutathione-S-transferase a3 expression. A, Murine kidney was used as a
positive control (original magnification 340) and B, a section of human
saphenous vein graft as a negative control (original magnification 320).
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TABLE E1. Human SNPs associated with graft occlusion in patients undergoing isolated CABG
SNP Ch Location OR P value Allele Symbol Annotation
rs279553 3 9909605 0.1 6.2E-05 A/G JAGN1 Jagunal homolog 1
rs1805124 3 38620424 5.1 8.4E-05 G/A SCN5A Voltage-gated Na channel type V-a
rs1330927 9 23421906 0.1 9.1E-05 A/C LOC402360 NOP56 ribonucleoprotein (9p21.3)
rs1541221 1 34556271 6.7 .0001 A/G C1orf94 Ch 1 open reading frame 94
rs588565 6 52900813 6.0 .0001 A/G GSTA3 Glutathione S-transferase a3
rs4705334 5 145802708 8.0 .0002 A/G TCERG1 Transcription elongation regulator 1
rs722212 4 11004173 11.4 .0002 A/G HS3ST1 Heparan sulfate 3-O-sulfotransferase 1
rs2996053 21 40312865 5.4 .0002 C/A DSCAM Down syndrome cell adhesion
rs602195 6 52908028 5.6 .0002 A/G GSTA3 Glutathione S-transferase a3
rs1886551 13 98364436 0.2 .0002 G/A DOCK9 Dedicator of cytokinesis 9
rs10507257 12 114172785 4.3 .0002 G/A TBX3 T-box 3
rs373552 6 52909987 5.6 .0003 G/A GSTA3 Glutathione S-transferase a3
rs378411 6 52912763 5.6 .0003 G/A GSTA3 Glutathione S-transferase a3
rs3823104 6 2728984 0.3 .0003 A/C WRNIP1 Werner helicase interacting protein 1
rs17459166 7 16268375 0.2 .0003 A/G hCG_1745121 Isoprenoid synthase domain
rs651733 6 52897787 5.2 .0003 A/G GSTA3 Glutathione S-transferase a3
rs3801734 7 81624853 4.6 .0004 G/A CACNA2D1 Voltage-gated Ca channel a2/delta-1
rs4980684 11 69249908 0.2 .0004 A/G FGF19 Fibroblast growth factor 19
CABG, Coronary artery bypass grafting; SNP, single nucleotide polymorphism; Ch, chromosome; OR, odds ratio.
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